These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 32774223)

  • 1. Metastatic Breast Cancer as a Chronic Disease: Evidence-Based Data on a Theoretical Concept.
    Elfgen C; Montagna G; Schmid SM; Bierbauer W; Güth U
    Breast Care (Basel); 2020 Jun; 15(3):281-288. PubMed ID: 32774223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Survival and Cure in Distant Metastatic Breast Cancer.
    Güth U; Elfgen C; Montagna G; Schmid SM
    Oncology; 2019; 97(2):82-93. PubMed ID: 31055570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noncompliance with palliative systemic therapy in patients with distant metastatic breast cancer: a blind spot for oncologists?
    Elfgen C; Montagna G; Schmid SM; Bierbauer W; Güth U
    Breast Cancer Res Treat; 2019 Jul; 176(2):469-476. PubMed ID: 31049829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review.
    Kobayashi T; Ichiba T; Sakuyama T; Arakawa Y; Nagasaki E; Aiba K; Nogi H; Kawase K; Takeyama H; Toriumi Y; Uchida K; Kobayashi M; Kanehira C; Suzuki M; Ando N; Natori K; Kuraishi Y
    Breast Cancer; 2012 Jul; 19(3):218-37. PubMed ID: 22532161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors.
    Berghoff AS; Bago-Horvath Z; Ilhan-Mutlu A; Magerle M; Dieckmann K; Marosi C; Birner P; Widhalm G; Steger GG; Zielinski CC; Bartsch R; Preusser M
    Br J Cancer; 2012 Oct; 107(9):1454-8. PubMed ID: 23047551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013.
    Le D; Speers C; Thompson L; Gondara L; Nichol A; Lohrisch C
    Cancer; 2020 Mar; 126(5):971-977. PubMed ID: 31750938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome and feasibility of palliative chemotherapy in very elderly patients with metastatic breast cancer.
    Overgaauw AJC; Speijers-van der Plas LM; Hendriks MP; Smorenburg CH
    Breast J; 2020 Mar; 26(3):433-439. PubMed ID: 31538705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival after high-dose chemotherapy with autologous hematopoietic cell transplantation in metastatic breast cancer.
    Hamilton BK; Rybicki L; Abounader D; Andresen S; Kalaycio M; Sobecks R; Pohlman B; Hanna R; Dean R; Liu H; Hill B; Bolwell B; Copelan E
    Hematol Oncol Stem Cell Ther; 2015 Sep; 8(3):115-24. PubMed ID: 26183670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distant metastatic breast cancer as an incurable disease: a tenet with a need for revision.
    Güth U; Huang DJ; Dirnhofer S; Rochlitz C; Wight E
    Cancer J; 2009; 15(1):81-6. PubMed ID: 19197181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes and metastatic behavior between de novo versus recurrent HER2-positive metastatic breast cancer: A 17-year single-institution cohort study at Taipei Veterans General Hospital.
    Cheng HF; Tsai YF; Huang CC; Lien PJ; Wang YL; Hsu CY; Chen YJ; Liu CY; Chao TC; Lin YS; Feng CJ; Chiu JH; Chau GY; Tseng LM
    J Chin Med Assoc; 2022 Jan; 85(1):88-94. PubMed ID: 34561409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors responsible for long-term survival in metastatic breast cancer.
    Kontani K; Hashimoto S; Murazawa C; Norimura S; Tanaka H; Ohtani M; Fujiwara-Honjo N; Date M; Teramoto K; Houchi H; Yokomise H
    World J Surg Oncol; 2014 Nov; 12():344. PubMed ID: 25395387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Features Associated With Long-Term Survival in Patients With Metastatic Breast Cancer.
    Klar N; Rosenzweig M; Diergaarde B; Brufsky A
    Clin Breast Cancer; 2019 Aug; 19(4):304-310. PubMed ID: 30827763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone metastases in breast cancer: Frequency, metastatic pattern and non-systemic locoregional therapy.
    Steinauer K; Huang DJ; Eppenberger-Castori S; Amann E; Güth U
    J Bone Oncol; 2014 May; 3(2):54-60. PubMed ID: 26909298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical predictors of long-term survival in HER2-positive metastatic breast cancer.
    Murthy P; Kidwell KM; Schott AF; Merajver SD; Griggs JJ; Smerage JD; Van Poznak CH; Wicha MS; Hayes DF; Henry NL
    Breast Cancer Res Treat; 2016 Feb; 155(3):589-95. PubMed ID: 26875184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic breast cancer in young women: a population-based cohort study to describe risk and prognosis.
    Tjokrowidjaja A; Lee CK; Houssami N; Lord S
    Intern Med J; 2014 Aug; 44(8):764-70. PubMed ID: 24863750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2-Positive Metastatic Breast Cancer: A Retrospective Cohort Study of Healthcare Costs in the Targeted-Therapy Age.
    Sussell JA; Sheinson D; Wu N; Shah-Manek B; Seetasith A
    Adv Ther; 2020 Apr; 37(4):1632-1645. PubMed ID: 32172510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016).
    Daniels B; Kiely BE; Lord SJ; Houssami N; Lu CY; Ward RL; Pearson SA
    Breast Cancer Res Treat; 2018 Aug; 171(1):151-159. PubMed ID: 29736743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
    Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
    Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database.
    Kaczmarek E; Saint-Martin C; Pierga JY; Brain E; Rouzier R; Savignoni A; Mouret-Fourme E; Dieras V; Piot I; Dubot C; Carton M; Lerebours F
    Breast Cancer Res Treat; 2019 Dec; 178(3):505-512. PubMed ID: 31486993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.